Evidence map›Paper›PMID 33037466›Full record

ArticleJournal of cancer research and clinical oncology2020

EPS15-NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma.

Shengzhuang Yang, Lijian Li, Dongsheng Chen, Mingzhe Xiao, Lei Xian

Abstract readCase ReportsLetter
In one paragraph

Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shengzhuang YangThe Second Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Lijian LiThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210002, China.
Dongsheng ChenThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210002, China.
Mingzhe XiaoThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210002, China.
Lei XianThe Second Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China. xianleigxykdx@163.com.ORCID http://orcid.org/0000-0002-0225-9900

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Oncogene Proteins, FusionAdaptor Proteins, Signal TransducingAdenocarcinoma of LungGenetic Association StudiesGenetic Predisposition to DiseaseGenetic TestingHumansImage-Guided BiopsyImmunohistochemistryIn Situ Hybridization, FluorescenceMaleMiddle AgedNeoplasm StagingReceptor, trkATomography, X-Ray ComputedAdaptor Proteins, Signal TransducingEPS15 protein, humanNTRK1 protein, humanOncogene Proteins, FusionReceptor, trkA

Identifiers

PMID33037466
PMCPMC11804275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.